T0	Limitation 31020 31026	First,
T1	Limitation 31074 31077	The
T2	Limitation 31338 31345	Second,
T3	Limitation 31419 31423	This
T4	Limitation 31878 31884	Third,
T5	Limitation 32406 32410	This
T6	FollowUpDuration 31027 31072	colchicine 0.5 mg was only given for 16 weeks
T7	FollowUpDuration 31173 31248	a more prolonged period of colchicine prophylaxis may have been appropriate
T8	PrecisionOfMeasurement 31346 31417	occurrence and duration of flares was dependent on patients’ assessment
T9	OutcomeMeasures 31447 31534	there are currently no validated endpoints for the assessment of gouty arthritis flares
T10	Generalization 31885 31987	the study population is probably not representative of all patients who would benefit from canakinumab
T11	Limitation 32191 32197	Fourth
T12	NonstandardTreatmentCharacteristics 32199 32404	allopurinol treatment was initiated at 300 mg (or 100 mg or 200 mg if creatinine clearance was <90 ml/min) instead of slowly up-titrating from a dose of 50–100 mg, as suggested in treatment recommendations
